This website uses cookies to enhance the user experience.
21st logo
||
AL

Ada Louise Heyerdahl Jervell1992

Shareholdings
19
Arrow
0
Double arrow
Norway Business roles
3

Roles

Management

NameRoleTotal operating incomeTotal equityShares
A
ANDRE INVESTERINGER AS
Managing Director/CEO
-
210,051
20 %
directly

Boards

NameRoleTotal operating incomeTotal equityShares
A
ANDRE INVESTERINGER AS
Board Member
-
210,051
20 %
directly
H
Holder
-
-
-
Last update: Apr 13, 2023

Related industries

1

Direct relationships

1

Shares owned by Ada Louise Heyerdahl Jervell

NameShare classTotal operating incomeTotal equityShare
A
ANDRE INVESTERINGER AS
Ordinære aksjer
0
210,051
20 %
directly
I
ININ GROUP AS
NO0010864036
5,569,000
183,328,000
< 0.01 %
directly
E
ELKEM ASA
NO0010816093
8,461,000,000
0
< 0.01 %
directly
N
NORSKE SKOG ASA
NO0010861115
92,000,000
4,199,000,000
< 0.01 %
directly
S
STOREBRAND ASA
NO0003053605
8,377,000,000
36,130,000,000
< 0.01 %
directly
A
AKER CARBON CAPTURE ASA
Closed
NO0010890304
6,000,000
4,841,000,000
< 0.01 %
directly
A
ARBION INDUSTRIES AS
NO0011037483
3,231,000
133,810,000
< 0.01 %
directly
A
AKER HORIZONS ASA
Closed
NO0010921232
0
4,048,000,000
< 0.01 %
directly
T
TOMRA SYSTEMS ASA
NO0012470089
3,546,000,000
1,744,000,000
< 0.01 %
directly
C
CAVENDISH HYDROGEN ASA
NO0013219535
490,000
88,733,000
< 0.01 %
directly
R
RANA GRUBER AS
NO0010907389
1,664,441,156
929,626,213
< 0.01 %
directly
N
NORDIC SEMICONDUCTOR ASA
NO0003055501
477,595,000
515,052,000
< 0.01 %
directly
N
NEL ASA
NO0010081235
103,455,000
5,445,241,000
< 0.01 %
directly
R
REC SILICON HOLDINGS AS
NO0010112675
0
16,124,000
< 0.01 %
directly
S
SCATEC ASA
NO0010715139
4,141,000,000
0
< 0.01 %
directly
N
NYKODE THERAPEUTICS ASA
NO0010714785
453,000
94,977,000
< 0.01 %
directly
V
VOW ASA
NO0010708068
0
684,000,000
< 0.01 %
directly
T
THOR MEDICAL ASA
NO0010597883
839,000
475,867,000
< 0.01 %
directly
B
BORREGAARD ASA
NO0010657505
0
2,318,680,000
< 0.01 %
directly

Limited to direct ownership positions of 0.5% or more.

Last update: Jun 2, 2025